US Patent 7622116 Method of treating inflammation using soluble IL-17RCX4

Patent 7622116 was granted and assigned to ZymoGenetics on November, 2009 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

All edits

Edits on 19 Oct, 2023

"update inverses"

Golden AI

edited on 19 Oct, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11788066 Antibody conjugates and methods of making and using the same

Edits on 17 Sep, 2023

"Add patent inventor(s)"

Golden AI

edited on 17 Sep, 2023

Edits made to:

Infobox (+4 properties)

Infobox

Patent Inventor Names

Mark W. Rixon0

Rolf E. Kuestner0

Steven D. Levin0

Zeren Gao0

Edits on 16 Sep, 2023

"Add patent abstract"

Golden AI

edited on 16 Sep, 2023

Edits made to:

Article (+449 characters)

Article

Patent abstract

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.

Edits on 24 May, 2023

"Remove website redirecting to Patent Public Search front page"

Golden AI

edited on 24 May, 2023

Edits made to:

Infobox (-1 properties)

Infobox

Official Website

https://pdfpiw.uspto.gov/.piw?Docid=076221160

Edits on 21 May, 2023

"Remove leading 0 from patent number"

Golden AI